Australia - English - Department of Health (Therapeutic Goods Administration)

viso aesthetics pty ltd - 44776 - electrosurgical system, general-purpose - the viso resonance device is electro surgical unit composed of main device, linear, roller and metallic glove hand piece. the device transmits radio frequency energy across a spectrum of frequencies to interact with skin cells. this results in improvements of skin texture, firmness and elasticity. radiofrequency applied through the roller handpiece or micro needles causes tissue coagulation and subsequent improvement in skin quality and scarring.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pegvisomant, quantity: 20 mg - injection, solution - excipient ingredients: water for injections - the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. the treatment goal is to normalise igf-1 levels.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pegvisomant, quantity: 15 mg - injection, solution - excipient ingredients: water for injections - the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. the treatment goal is to normalise igf-1 levels.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pegvisomant, quantity: 10 mg - injection, solution - excipient ingredients: water for injections - the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. the treatment goal is to normalise igf-1 levels.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - nortriptyline hydrochloride, quantity: 11.4 mg (equivalent: nortriptyline, qty 10 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - nortriptyline hydrochloride, quantity: 28.5 mg (equivalent: nortriptyline, qty 25 mg) - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - nortriptyline, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; hypromellose; glycerol; maize starch; calcium phosphate; sunset yellow fcf aluminium lake - allegron is indicated for the treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - nortriptyline, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; calcium phosphate; maize starch; glycerol; magnesium stearate - allegron is indicated for the treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pegvisomant, quantity: 20 mg - injection, solution - excipient ingredients: water for injections - the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. the treatment goal is to normalise igf-1 levels.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pegvisomant, quantity: 15 mg - injection, solution - excipient ingredients: water for injections - the treatment of acromegaly in patients who have had inadequate response to surgery and/or radiation and/or other medical therapies or for whom these therapies are not appropriate. the treatment goal is to normalise igf-1 levels.